Circadian Technologies (ASX: CIR, OTCQX:CKDXY) has announced the retirement of two board members, with Dr Jonathan Skipper to retire as a director on the board in November, with Carlo Montagner to retire later this month.
Circadian chairman, Ms Dominique Fisher, said “On behalf of the board and the shareholders of Circadian, I thank both Jonathan and Carlo for their valuable contributions and commercial insights over the years.
"While it is disappointing to lose them as Directors we are glad that we will maintain their expertise through their ongoing roles with Circadian’s Product Development Review Committee.”
Circadian is currently in a very interesting phase, and just last week announced that the company had taken a significant step forward, filing a new drug application to the U.S. Food and Drug Administration (FDA) to start clinical studies for its VGX-100 antibody to treat cancer.
An Investigational New Drug Application (NYSE:IND) is a request for authorisation from the U.S. Food and Drug Administration (FDA) to administer an investigational drug to humans.
The first trial or Phase I will involve the treatment of a variety of different cancer types in patients with late stage cancer.
Circadian is focussed on developing VGX-100 (a human antibody against VEGF-C) as a treatment for solid tumours - including glioblastoma and colorectal cancer - as the first target indications for VGX-100.
VGX-100 works by blocking the growth of lymphatics. Circadian has already invested considerably in the VGX-100 molecule in terms of manufacturing, toxicology studies and other pre-clinical activities.